Nanobiotix S.A. (NBTX)
NBTX Stock Price Chart
Explore Nanobiotix S.A. interactive price chart. Choose custom timeframes to analyze NBTX price movements and trends.
NBTX Company Profile
Discover essential business fundamentals and corporate details for Nanobiotix S.A. (NBTX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
11 Dec 2020
Employees
108.00
Website
https://www.nanobiotix.comCEO
Laurent Levy
Description
Nanobiotix S.A. is a clinical-stage biotechnology firm focused on developing innovative therapeutic solutions for cancer. The company's leading experimental drug, NBTXR3, is a sterile aqueous suspension comprising crystalline hafnium oxide nanoparticles. This treatment is currently undergoing development for its potential application in a broad spectrum of cancers, including soft tissue sarcoma, various head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has established a strategic collaboration with LianBio for the development and commercialization of NBTXR3 within key Asian markets, specifically Greater China, South Korea, Singapore, and Thailand. Founded in 2003, the company's main operations are situated in Paris, France.
NBTX Financial Timeline
Browse a chronological timeline of Nanobiotix S.A. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 30 Sept 2026
EPS estimate is -$0.32, while revenue estimate is $19.92m.
Earnings released on 31 Mar 2026
EPS came in at -$0.46 falling short of the estimated $0.30 by -250.74%, while revenue for the quarter reached $3.53m , missing expectations by -93.15%.
Earnings released on 30 Sept 2025
EPS came in at -$0.13 surpassing the estimated -$0.25 by +45.89%, while revenue for the quarter reached $31.36m , beating expectations by +31.22%.
Earnings released on 2 Apr 2025
EPS came in at -$1.01 falling short of the estimated -$0.62 by -63.46%, while revenue for the quarter reached -$21.64m , missing expectations by -709.22%.
Earnings released on 12 Nov 2024
EPS came in at -$0.50 surpassing the estimated -$0.51 by +2.47%, while revenue for the quarter reached $9.99m , missing expectations by -3.45%.
Earnings released on 24 Apr 2024
EPS came in at -$0.33 surpassing the estimated -$0.83 by +60.40%, while revenue for the quarter reached $36.20m .
Earnings released on 13 Nov 2023
EPS came in at -$0.87 falling short of the estimated -$0.59 by -47.60%, while revenue for the quarter reached $3.59m , missing expectations by -9.09%.
Earnings released on 28 Mar 2023
EPS came in at -$0.95 , while revenue for the quarter reached $1.86m .
Earnings released on 9 Nov 2022
EPS came in at -$0.79 , while revenue for the quarter reached $695.08k .
Earnings released on 30 Mar 2022
EPS came in at -$0.54 surpassing the estimated -$1.05 by +48.56%, while revenue for the quarter reached $752.78k , missing expectations by -47.33%.
Earnings released on 9 Aug 2021
EPS came in at -$1.04 falling short of the estimated -$0.60 by -73.76%, while revenue for the quarter reached $11.86k , beating expectations by +3.76%.
NBTX Stock Performance
Access detailed NBTX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
